Transformational therapies demand a new mindset
Pharma is moving to a new era of radical new therapies, presenting unexpected and difficult challenges.
Transforming value real-world evidence
Existing measures and endpoints may not capture the value and improvements offered by novel interventions, especially in rare disease. Rob Arbuckle explores data collection and the need for collaboration to define what is meaningful change and how it is shown.
Transforming value evidence for market access
Louise Heron discusses the challenges faced by transformative therapies in HTA submissions, and the need to change the way we plan for and demonstrate cost effectiveness and the value offering.
Transforming value – patient centered outcomes
Existing measures and endpoints may not capture the value and improvements offered by novel interventions, especially in rare disease. Rob Arbuckle explores data collection and the need for collaboration to define what is meaningful change and how it is shown.
Transformational medicine in medical affairs
Chris Gray, President Innovation, Engagement and Ventures at Adelphi in Healthcare discusses some of the outcomes from the Adelphi Renaissance series and what that means for medical affairs.
